Transforming Lung Cancer Management with AI and Biomarkers: From Early Detection to Targeted Therapies
- Department of Biotechnology, Vivekanandha College of Arts and Sciences for Women (Autonomous), Elayampalayam, Tiruchengode, Tamil Nadu, India
* Correspondence: gnani.science@gmail.com
Abstract
Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) representing the primary histological subtypes. Approximately 85% of cases are classified as NSCLC, whereas SCLC is characterized by its aggressive clinical course and poor prognosis. Major risk factors for SCLC include smoking, environmental exposures, and genetic predispositions. Early detection is critical; low-dose computed tomography (LDCT) has demonstrated a significant reduction in lung cancer–specific mortality. The use of biomarkers, such as microRNAs (miRNAs), has enhanced diagnostic accuracy by improving risk stratification and distinguishing malignant from benign pulmonary nodules. Artificial intelligence (AI)-driven imaging technologies have revolutionized lung cancer screening by increasing diagnostic precision and operational efficiency. Advances in molecular characterization, including identification of mutations and gene fusions involving EGFR, KRAS, ALK, and NTRK, have facilitated the development of personalized therapeutic strategies. In particular, immunotherapies and targeted agents, such as TRK inhibitors, have demonstrated promising efficacy in NSCLC. Nevertheless, significant challenges remain, including therapy resistance, healthcare disparities, and limited accessibility to screening programs. Emerging technologies, such as liquid biopsies and deep learning–enhanced imaging, continue to drive improvements in early detection and treatment paradigms. Future research should prioritize the integration of AI, novel therapeutics, and precision medicine approaches to optimize lung cancer management. By advancing early diagnostic capabilities, expanding personalized interventions, and addressing disparities in access to care, meaningful progress can be achieved in reducing lung cancer mortality.
Keywords
Author information
Authors and Affiliations
Department of Biotechnology, Vivekanandha College of Arts and Sciences for Women (Autonomous), Elayampalayam, Tiruchengode, Tamil Nadu, India
Priyadharshini Balasubramani & Gnanendra Shanmugam
Corresponding author
Correspondence to Gnanendra Shanmugam (gnani.science@gmail.com).
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, provided appropriate credit is given to the original author(s) and the source, a link to the licence is provided, and any changes are indicated. Images or other third-party material in this article are included in the article’s licence unless stated otherwise in a credit line to the material. © 2025 The Author(s).
About this article
Cite this article
Balasubramani P, Shanmugam G. Transforming Lung Cancer Management with AI and Biomarkers: From Early Detection to Targeted Therapies. Int J Adv Interdis Res. 2025;5:e004. https://doi.org/10.29191/ijaidr.2025.05.e004
Download citation (RIS) · BibTeX ·
- Received01 May 2025
- Revised06 May 2025
- Accepted10 May 2025
- Published12 May 2025
- DOIhttps://doi.org/10.29191/ijaidr.2025.05.e004
Share this article
Anyone you share the following link with will be able to read this article: